

A list of all abbreviations and terms appearing in this issue of *Therapy*.

A	Acute	FDP5	Finnish Diabetes Prevention Study	MEC	Moderately emetogenic chemotherapy
ACCORD	Action to Control Cardiovascular Risk in Diabetes	FIELD	Fenofibrate Intervention and Event Lowering in Diabetes	MI	Myocardial infarction
ACE	Angiotensin-converting enzyme	FISH	Fluorescence <i>in situ</i> hybridization	MPM	Malignant pleural mesothelioma
ACTH	Adrenocorticotrophic hormone	FL	Follicular lymphoma	MZL	Marginal zone lymphoma
ADCC	Antibody-dependent cytotoxicity	FLIE	Functional Living Index of Emesis	NCI-WG	National Cancer Institute Sponsored Working Group
ALT	Alanine transaminase	FOLFIRI	5-FU, LV and irinotecan	NCLB	<i>N</i> -desmethyl clobazam
AMI	Acute myocardial infarction	FVC	Forced vital capacity	NHL	Non-Hodgkin lymphoma
ANP	Atrial natriuretic peptide	GARFT	Glycinamide ribonucleotide formyl transferase	NK1	Novel neurokinin 1
ARB	Angiotensin receptor blocker	GFR	Glomerular filtration rate	NR	Not reported
ASC	Active supportive care	GI	Gastrointestinal	NSCLC	Non-small-cell lung cancer
AUC	Area under the curve	Hb	Hemoglobin	OCT	Organic cation transporter
BAS	Bile acid sequestrant	HCP	Healthcare provider	OR	Overall response
BB	$\beta$ -blocker	HDL-C	High-density lipoprotein cholesterol	PAR2	Protease-activated receptor-2
BMI	Body mass index	HEC	Highly emetogenic chemotherapy	PDGFR	Platelet-derived growth factor receptor
CAD	Coronary artery disease	HEC	Highly emetogenic chemotherapy	PFS	Progression-free survival
CAPPP	Captopril Prevention Project	HER2	Human epidermal growth factor receptor 2	PNA5	Purine nucleoside analogs
CCB	Calcium channel blocker	HF	Heart failure	PR	Partial responses
CCR	Cardioprotective regimen	HMGCR	HMG-CoA reductase	PVD	Peripheral vascular disease
CETP	Cholesteryl ester transfer protein	HOPE	Heart Outcomes Prevention Evaluation	QoL	Quality of life
CI	Confidence interval	HOT	Hypertension Optimal Treatment	RAAS	Renin-angiotensin-aldosterone system
CINV	Chemotherapy-induced nausea and vomiting	Hp	Haptoglobin	RBC	Red blood cell
CKD	Chronic kidney disease	IBC	Inflammatory breast cancer	RDA	Recommended dietary allowance
CLL	Chronic lymphocytic leukemia	IBS	Irritable bowel syndrome	RECIST	Response Evaluation Criteria In Solid Tumors
CR	Complete response	IBS-C	Constipation predominant IBS	SERT	Serotonin reuptake transporter
CRF	Corticotropin-releasing hormone	IBS-D	Diarrhea predominant IBS	SSRI	Selective serotonin reuptake inhibitor
CT	Computed tomography	IBS-M	Mixed pattern IBS	SVC	Slow vital capacity
CTTC	Cholesterol Treatment Trialists Collaborators	IDPP-1	Indian Diabetes Prevention Program	T1WI	T1-weighted image
CVD	Cardiovascular disease	IFG	Impaired fasting glycemia	T2DM	Type 2 diabetes mellitus
CY	Cyclophosphamide	Ig	Immunoglobulin	T2WI	T2-weighted image
D	Delayed	IGFR-1	Insulin-like growth factor-1	TG	Triglyceride
DCCT	Diabetes Control and Complications Trial	IGT	Impaired glucose tolerance	TPA	Tissue plasminogen activator
DHFR	Dihydrofolate reductase	IHC	immunohistochemistry	TPH	Tryptophan hydroxylase
DIAD	Detection of Ischemia in Asymptomatic Diabetics	IL	Intensive lifestyle	TRPV1	Transient receptor potential vanilloid 1
DKD	Diabetic kidney disease	LDL-C	Low-density lipoprotein cholesterol	TS	Thymidine synthase
DM	Diabetes mellitus	LIFE	Losartan Intervention for Endpoint Reduction	TTP	Time-to-progression
DPP	Diabetes Prevention Program	LVH	Left ventricular hypertrophy	TZD	Thiazolidinedione
ECD	Extracellular domain	mAbs	Monoclonal antibodies	UKPDS	UK Prospective Diabetes Study
EDIC	Epidemiology of Diabetes Interventions and Complications	MASCC	Multinational Association of Supportive Care in Cancer	ULN	Upper limit normal
EGFR	Epidermal growth factor receptor	MBC	Metastatic breast cancer	VADT	Veterans Affairs Diabetes Trial
eGFR	Estimated glomerular filtration rate	MEC	Moderately emetogenic chemotherapy	VEGF	Vascular endothelial growth factor
EPP	Extra-pleural pneumonectomy			VLCD	Very low calorie diet
ER	Estrogen receptor				
ESRD	End-stage renal disease				
FA	Fludarabine				